A phase II Study of Bevacizumab plus oral S1 previously treated non-small cell lung Cancer (OSAKA-LCSG1202)

Trial Profile

A phase II Study of Bevacizumab plus oral S1 previously treated non-small cell lung Cancer (OSAKA-LCSG1202)

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2017 Status changed from recruiting to completed.
    • 01 Jun 2017 Primary endpoint (Objective clinical response rate) has not been met as per the results published in the Cancer Chemotherapy and Pharmacology
    • 01 Jun 2017 Results published in the Cancer Chemotherapy and Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top